{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:21:20Z","timestamp":1790230880860,"version":"4.1.0"},"reference-count":78,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Systemic chemotherapies for advanced or metastatic thyroid carcinomas have been of only limited effectiveness. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, novel therapies are needed to improve disease outcomes.<\/jats:p>\n               <jats:p>Evidence Acquisition: The PubMed and Google Scholar search engines were used to identify publications and peer-reviewed meeting presentations addressing chemotherapy and targeted therapy for differentiated or medullary carcinoma.<\/jats:p>\n               <jats:p>Evidence Synthesis: Multiple novel therapies primarily targeting angiogenesis have entered clinical trials for metastatic thyroid carcinoma. Partial response rates up to 30% have been reported in single agent studies, but prolonged disease stabilization is more commonly seen. The most successful agents target the vascular endothelial growth factor receptors, with potential targets including the mutant kinases associated with papillary and medullary oncogenesis. Two drugs approved for other malignancies, sorafenib and sunitinib, have had promising preliminary results reported, and are being used selectively for patients who do not qualify for clinical trials. Randomized trials for several agents are underway that may lead to eventual drug approval for thyroid cancer.<\/jats:p>\n               <jats:p>Conclusion: Treatment for patients with metastatic or advanced thyroid carcinoma now emphasizes clinical trial opportunities for novel agents with considerable promise. Alternative options now exist for use of tyrosine kinase inhibitors that are well tolerated and may prove worthy of regulatory approval for this disease.<\/jats:p>","DOI":"10.1210\/jc.2008-0923","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T03:04:07Z","timestamp":1236135847000},"page":"1493-1499","source":"Crossref","is-referenced-by-count":76,"title":["Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers"],"prefix":"10.1210","volume":"94","author":[{"given":"Steven I.","family":"Sherman","sequence":"first","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230-1402"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613281854100_R1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1098-2388(199901\/02)16:1<34::AID-SSU7>3.0.CO;2-2","article-title":"Management of the patient with progressive radioiodine non-responsive disease.","volume":"16","author":"Haugen","year":"1999","journal-title":"Semin Surg Oncol"},{"key":"2020071613281854100_R2","first-page":"429","article-title":"Clinical trials for thyroid carcinoma: past, present, and future","author":"Sherman","year":"2006","journal-title":"In: Mazzaferri EL, Harmer C, Mallick UK, Kendall-Taylor P, eds. Practical management of thyroid cancer: a multidisciplinary approach. London: Springer-Verlag;"},{"key":"2020071613281854100_R3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2020071613281854100_R4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2020071613281854100_R5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/joe.1.05895","article-title":"How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.","volume":"183","author":"Fagin","year":"2004","journal-title":"J Endocrinol"},{"key":"2020071613281854100_R6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of angiogenesis and arteriogenesis.","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat Med"},{"key":"2020071613281854100_R7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target.","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"2020071613281854100_R8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/jcem.86.2.7226","article-title":"Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.","volume":"86","author":"Klein","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613281854100_R9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/msy.2001.112592","article-title":"Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer.","volume":"129","author":"Lennard","year":"2001","journal-title":"Surgery"},{"key":"2020071613281854100_R10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/thy.2006.16.109","article-title":"Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.","volume":"16","author":"Cooper","year":"2006","journal-title":"Thyroid"},{"key":"2020071613281854100_R11","unstructured":"Sherman\n              SI\n            \n          \n          2008\n          NCCN practice guidelines for thyroid cancer, version 2008. Available at: www.nccn.org. Last accessed December 2, 2008"},{"key":"2020071613281854100_R12","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2008.17.3682","article-title":"Refractory thyroid cancer: a paradigm shift in treatment is not far off.","volume":"26","author":"Pfister","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/13543784.12.1.51","article-title":"Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.","volume":"12","author":"Laird","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"2020071613281854100_R14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/CCO.0b013e32801173ea","article-title":"Medullary thyroid cancer: therapeutic targets and molecular markers.","volume":"19","author":"Ball","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"2020071613281854100_R15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/thy.2000.10.587","article-title":"Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion.","volume":"10","author":"Ain","year":"2000","journal-title":"Thyroid"},{"key":"2020071613281854100_R16","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","article-title":"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.","volume":"66","author":"Polverino","year":"2006","journal-title":"Cancer Res"},{"key":"2020071613281854100_R17","first-page":"920","article-title":"Anti-tumor activity of AMG 706, an oral multi-kinase inhibitor, in human medullary thyroid carcinoma xenografts","volume":"16","author":"Coxon","year":"2006","journal-title":"Thyroid"},{"key":"2020071613281854100_R18","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2006.07.8170","article-title":"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.","volume":"25","author":"Rosen","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer.","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"2020071613281854100_R20","article-title":"Phase II study of safety and efficacy of motesanib (AMG 706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","author":"Schlumberger","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"key":"2020071613281854100_R22","article-title":"Exacerbation of postsurgical hypothyroidism during treatment of thyroid carcinoma with motesanib diphosphate (AMG 706)","author":"Sherman","year":"2007"},{"key":"2020071613281854100_R23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"2020071613281854100_R24","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R25","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R26","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","article-title":"Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.","volume":"64","author":"Bocci","year":"2004","journal-title":"Cancer Res"},{"key":"2020071613281854100_R27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/13543784.16.2.239","article-title":"Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.","volume":"16","author":"Herbst","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"2020071613281854100_R28","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res"},{"key":"2020071613281854100_R29","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"2020071613281854100_R30","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"2020071613281854100_R31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdi247","article-title":"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.","volume":"16","author":"Holden","year":"2005","journal-title":"Ann Oncol"},{"key":"2020071613281854100_R32","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1200\/jco.2007.25.18_suppl.6018","article-title":"Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial","volume":"25","author":"Wells Jr","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R33","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/0008-5472.CAN-06-4605","article-title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.","volume":"67","author":"Akeno-Stuart","year":"2007","journal-title":"Cancer Res"},{"key":"2020071613281854100_R34","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1200\/jco.2008.26.15_suppl.6024","article-title":"A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"26","author":"Haddad","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R35","article-title":"Molecular targeted therapeutics in medullary thyroid carcinoma: results of recent clinical trials","author":"Wells","year":"2009"},{"key":"2020071613281854100_R36","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"2020071613281854100_R37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants.","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2020071613281854100_R38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"2020071613281854100_R39","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R40","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1200\/jco.2006.24.18_suppl.5534","article-title":"Significant clinical and biologic activity of RAF\/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II study","volume":"24","author":"Kloos","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R41","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer.","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R42","doi-asserted-by":"crossref","first-page":"14065","DOI":"10.1200\/jco.2007.25.18_suppl.14065","article-title":"Effect of sorafenib in symptomatic metastatic medullary thyroid cancer","volume":"25","author":"Kober","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R43","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/jco.2008.26.15_suppl.3593","article-title":"Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156)","volume":"26","author":"Chintala","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R44","article-title":"First successful use of sorafenib to treat pediatric papillary thyroid carcinoma (PTC)","author":"Waguespack","year":"2007","journal-title":"Thyroid"},{"key":"2020071613281854100_R45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy.","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2020071613281854100_R46","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1210\/jc.2005-2845","article-title":"An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET\/papillary thyroid cancer kinases.","volume":"91","author":"Kim","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613281854100_R47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7326\/0003-4819-148-7-200804010-00027","article-title":"Response to sunitinib in medullary thyroid cancer","volume":"148","author":"Kelleher","year":"2008","journal-title":"Ann Intern Med"},{"key":"2020071613281854100_R48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CAD.0b013e3282fc6cf7","article-title":"Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.","volume":"19","author":"Dawson","year":"2008","journal-title":"Anticancer Drugs"},{"key":"2020071613281854100_R49","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1200\/jco.2008.26.15_suppl.6025","article-title":"Phase 2 study of sunitinib in refractory thyroid cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R50","doi-asserted-by":"crossref","unstructured":"Ravaud\n              A\n            , de la Fouchardie\u0300reC, CourbonF, AsselineauJ, KleinM, Nicoli-SireP, BournaudC, DelordJ, WeryhaG, CatargiB\n          2008\n          Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. Available at: http:\/\/www.asco.org\/ASCO\/abstracts+%26+virtual+meeting\/abstracts?&vmview=abst_detail_view&confID=55&abstractID=33144. Last accessed December 15, 2008","DOI":"10.1200\/jco.2008.26.15_suppl.6058"},{"key":"2020071613281854100_R51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.surg.2005.10.019","article-title":"Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia type 2A and 2B associated RET mutations.","volume":"139","author":"de Groot","year":"2006","journal-title":"Surgery"},{"key":"2020071613281854100_R52","first-page":"3601","article-title":"RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.","volume":"23","author":"Skinner","year":"2003","journal-title":"Anticancer Res"},{"key":"2020071613281854100_R53","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38","author":"Buchdunger","year":"2002","journal-title":"Eur J Cancer"},{"key":"2020071613281854100_R54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/EJE-06-0695","article-title":"Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.","volume":"157","author":"Frank-Raue","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2020071613281854100_R55","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2007-0649","article-title":"A phase-II trial of imatinib therapy for metastatic medullary thyroid carcinoma.","volume":"92","author":"de Groot","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613281854100_R56","doi-asserted-by":"crossref","first-page":"13048","DOI":"10.1200\/jco.2006.24.18_suppl.13048","article-title":"Phase I\/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic medullary thyroid carcinomas (MTC)","volume":"24","author":"Hoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R57","first-page":"5749","article-title":"ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.","volume":"62","author":"Wakeling","year":"2002","journal-title":"Cancer Res"},{"key":"2020071613281854100_R58","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"2020071613281854100_R59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2007.0120","article-title":"A phase II study of gefitinib in patients with advanced thyroid cancer.","volume":"18","author":"Pennell","year":"2008","journal-title":"Thyroid"},{"key":"2020071613281854100_R60","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-006-0286-6","article-title":"A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.","volume":"59","author":"Fury","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020071613281854100_R61","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1517\/13543776.17.9.1035","article-title":"Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications.","volume":"17","author":"Cui","year":"2007","journal-title":"Expert Opin Ther Pat"},{"key":"2020071613281854100_R62","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1210\/en.2003-1762","article-title":"Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.","volume":"145","author":"Mineo","year":"2004","journal-title":"Endocrinology"},{"key":"2020071613281854100_R63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/01.pas.0000156103.37756.e2","article-title":"MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma.","volume":"29","author":"Wasenius","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"2020071613281854100_R64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/EP:11:1:19","article-title":"Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid.","volume":"11","author":"Papotti","year":"2000","journal-title":"Endocr Pathol"},{"key":"2020071613281854100_R65","first-page":"119","article-title":"including a subgroup of pts with medullary thyroid cancer (MTC)","volume-title":"Proc 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","author":"Kurzrock","year":"2008"},{"key":"2020071613281854100_R66","first-page":"120","article-title":"administered orally to patients with advanced solid tumors","volume-title":"Proc 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","author":"Schwartz","year":"2008"},{"key":"2020071613281854100_R67","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071613281854100_R68","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/thy.2006.0289","article-title":"Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas.","volume":"17","author":"Ain","year":"2007","journal-title":"Thyroid"},{"key":"2020071613281854100_R69","unstructured":"Ain\n              KB\n            , LeeC, HolbrookKM, DzibaJM, WilliamsKD\n          2008\n          Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. Available at: http:\/\/www.asco.org\/ASCO\/abstracts+&+virtual+meeting\/abstracts?&vmview=abst_detail_view&confID=55&abstractID=30832. Last accessed February 2, 2009"},{"key":"2020071613281854100_R70","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1210\/jcem-71-3-755","article-title":"Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro.","volume":"71","author":"Van Herle","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613281854100_R71","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1530\/eje.0.1480395","article-title":"Retinoic acid for redifferentiation of thyroid cancer\u2014does it hold its promise?","volume":"148","author":"Gruning","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"2020071613281854100_R72","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/eje.1.02123","article-title":"Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.","volume":"154","author":"Liu","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071613281854100_R73","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1200\/jco.2006.24.18_suppl.5554","article-title":"A phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: preliminary toxicity and efficacy experience","volume":"24","author":"Su","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R74","first-page":"966","article-title":"A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer","author":"Kebebew","year":"2006","journal-title":"Surgery 140:960\u2013966; discussion"},{"key":"2020071613281854100_R75","first-page":"928","article-title":"Phase II study of oral histone deacetylase inhibitor SAHA in patients with metastatic thyroid cancer.","volume":"14","author":"Ringel","year":"2006","journal-title":"Thyroid"},{"key":"2020071613281854100_R76","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/jco.2007.25.18_suppl.3547","article-title":"Combination of 5-azacytidine (5-AZA) and valproic acid (VPA) in advanced solid cancers: a phase I study","volume":"25","author":"Soriano","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020071613281854100_R77","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy.","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2020071613281854100_R78","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2008.10.031","article-title":"Lessons learned from independent central review.","volume":"45","author":"Ford","year":"2009","journal-title":"Eur J Cancer"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/5\/1493\/9062339\/jcem1493.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/5\/1493\/9062339\/jcem1493.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:53:55Z","timestamp":1594943635000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/5\/1493\/2597810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,1]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-0923","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,1]]}}}